| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We have developed a new technology to enhance immune responses by generating complex which composed DNA-binding protein fused vaccine antigen, DNA and nano-particle glycogen (NPG). In this system, NPG was used as scaffold material, DNA was used as crosslinker material for vaccine antigen and NPG. New tricomponent vaccine complex (DBP-Vaccine/DNA/NPG) function was evaluated using an ookinete surface protein of Plasmodium vivax, Pvs25. The tricomplex immunized mice were conferred a high immune response compared to Pvs25 alone or DBP-Pvs25/DNA complex immunized groups. This system may be a promising approach for development of subunit vaccines against malaria.
|
